San Francisco, CA (May 4, 2021) – Fenwick today announced the arrival of Key Shin as a technology transactions partner in the firm’s highly regarded Life Sciences practice.
Based in the firm’s San Francisco office, Key Shin works closely with public and private Life Sciences companies and focuses on a broad set of transactions, including licensing, pharma partnering, supply, and clinical development, for biopharmaceutical, medical devices and digital health companies.
“Fenwick’s Life Sciences practice has expanded significantly in the last several years, and Key’s substantial experience will enable us to further deepen our relationships with a growing stable of cutting-edge life sciences clients,” said Fenwick Chair Richard Dickson.
“Our Life Sciences practice continues to see strong demand and growth from early stage through public offerings,” said Fenwick Intellectual Property Practice Chair Rajiv Patel. “Key’s role as a well-respected deal lawyer adds further depth and expertise to our platform to provide strategic advice and counseling for a wide range of transactions in the life sciences sector.”
“Fenwick’s special concentration on the life sciences and technology industries and its collaborative culture set it apart,” Key Shin said. “I am thrilled to be part of a team that has such a deep and specialized understanding of their clients’ business and technologies.”
“We continue to have growing demand for sophisticated deal support, such as pharma partnering, co-development and co-commercialization transactions, from our emerging companies as well as companies that have grown and matured, including several large public companies,” said Stefano Quintini, who co-chairs the Life Sciences group. “Key’s addition complements our team and helps position us to further capitalize on the industry momentum.”
Key Shin joins Fenwick as the firm continues to invest in expanding in key strategic areas to serve its growing client base. The firm most recently added Per Chilstrom and Michael Pilo in New York to boost its national Capital Markets & Public Companies team.
About Fenwick’s Life Sciences Group
Fenwick’s Life Sciences practice represents some of the most successful biopharma, medical device, diagnostic and healthcare companies from conception through strategic mergers and acquisitions, public offerings, and post public representation. The firm’s cross-disciplinary teams—many with prior careers in the Life Sciences industry as general counsel, scientists, bankers and regulatory employees—partner with leading companies on their most business-critical legal needs. The Life Sciences team has been recognized by Chambers USA and recommended nationally for licensing and collaborations, patent prosecution and patent strategy and management by LMG Life Sciences.
Fenwick provides comprehensive legal services to leading technology and life sciences companies — at every stage of their lifecycle — and the investors that partner with them. We craft innovative, cost-effective and practical solutions in areas ranging from venture capital, public offerings, joint ventures, M&A and strategic relationships, to intellectual property, litigation and dispute resolution, taxation, antitrust and employment and labor law. For more than four decades, Fenwick has helped some of the world's most recognized companies become and remain market leaders. For more information, please explore fenwick.com.